On the heels of the launch of an online direct-to-patient (DTP) program offering discounted Eliquis to certain U.S. patients, Bristol Myers Squibb is putting Sotyku at the center of its next DTP ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus erythematosus and plaque psoriasis, and $300 million in funds from Bain Capital.

BioNTech SE and Bristol Myers Squibb have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 across numerous ...

Bristol Myers Squibb, Board Chair of BMS and CEO Christopher Boerner, PhD, have committed the pharma giant to investing $40 billion over the next five years toward U.S. research and development (R&D), ...

Automotive BMS must undergo rigorous testing to verify that it meets stringent performance and safety standards. BMS emulation involves using hardware and software tools to simulate the behavior of a ...

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts. Bristol Myers ...

Battery management system (BMS) hardware and software continue to evolve as electric vehicles (EVs) transition to 800-V Li-ion battery systems comprising around 200 individual cells connected in ...

Integrated into battery management systems (BMS), an analog front end (AFE) digitizes and processes key inputs to ensure safe and efficient operation. While AFEs play a crucial role in electric ...

BMS Re, the reinsurance arm of global broker BMS Group, has appointed Brad Melvin (pictured above) as president and chief executive officer of BMS Re US, effective in November. Melvin will report to ...

Bristol Myers Squibb is axing another big bet from the Caforio era, terminating a deal for Agenus’ TIGIT bispecific antibody three years after paying $200 million to buy into the program. Agenus ...

Bristol Myers Squibb has had a whiplash change of heart on its BCMA bispecific T-cell engager, halting (PDF) further development months after filing to run a phase 3 trial. The Big Pharma disclosed ...